0001193125-26-047544
SEC filingQuince Therapeutics, Inc. reported preliminary cash and investments of $17.7 million as of December 31, 2025, against $16.4 million outstanding on its EIB Loan. The Company engaged LifeSci Capital to pursue strategic alternatives, primarily a reverse merger, following the failure of its lead drug candidate eDSP in the NEAT clinical trial.